Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several statements are broadly consistent with label-supported concepts (mechanism of HMG-CoA reductase inhibition in liver; LDL-C lowering; risk of liver enzyme elevations with specified testing). However, many liver-cancer/hepatitis/fatty liver/quantified incidence and genetic-risk claims are not supported by the provided label excerpts, and the response introduces additional safety details without label support.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication.
Label context includes mechanism as an HMG-CoA reductase inhibitor (Section 12.1) and refers to “other drugs in this class” (Sections 5.1, 7).
Lipitor works by inhibiting the production of cholesterol in the liver.
Atorvastatin is a competitive inhibitor of HMG-CoA reductase and “The liver is the primary site of action” (Section 12.1).
Lipitor lowers low-density lipoprotein (LDL) cholesterol levels.
Label indicates it reduces LDL-C (Sections 1.2 and 14.2).
Lipitor is effective for lowering cholesterol levels.
Label: “LIPITOR reduces total-C, LDL-C… and increases HDL-C…” and clinical studies sections describe reductions (Sections 14.2 and 14.1/14.2).
Liver damage is a rare but serious side effect of Lipitor.
Label discusses persistent elevations in transaminases in 0.7% and serious adverse reactions including hepatic failure in postmarketing experience (Sections 5.2 and 6.2). (Exact “rare” phrasing and implication are not directly stated.)
Regular blood tests can help detect changes in liver function while taking Lipitor.
Recommended: liver function tests prior to and at 12 weeks following initiation and dose increase, and periodically thereafter (Section 5.2).
The risk of liver damage from Lipitor is relatively low but not zero.
Transaminase elevations in 0.7% in trials (Section 5.2) indicates low incidence; label also includes contraindication for active liver disease (Sections 4.1 and 5.2), and postmarketing hepatic failure (Section 6.2).
Symptoms of liver damage from Lipitor may include fatigue, nausea, abdominal pain, and jaundice.
Not supported by the provided label excerpts (no symptom list provided in provided sections).
Unsupported Statements
Liver damage from Lipitor occurs in approximately 0.1% of patients taking the medication.
Provided label excerpt gives persistent transaminase elevations in 0.7% (Section 5.2) but does not support 0.1% nor equate this to “liver damage.”
In rare cases, Lipitor can cause liver failure.
Provided label excerpt lists hepatic failure in postmarketing experience (Section 6.2) but does not state “rare cases.”
Liver failure from Lipitor can lead to the need for a liver transplant.
No transplant requirement is mentioned in the provided label excerpts.
There is some evidence that long-term use of Lipitor may increase the risk of liver cancer.
No liver-cancer risk statement is present in the provided label excerpts.
Lipitor can contribute to the development of fatty liver disease.
No statement about fatty liver disease development is present in the provided label excerpts.
Fatty liver disease is characterized by the accumulation of fat in liver cells.
This is general disease definition; no label support is provided in the excerpt.
Lipitor has been linked to hepatitis.
The provided excerpts do not mention hepatitis linkage.
Hepatitis is inflammation of the liver.
General definition; not supported by the provided label excerpts.
Older adults may be more likely to experience liver damage due to Lipitor.
No age-associated liver-damage statement is present in the provided label excerpts.
Individuals with pre-existing liver conditions such as hepatitis or cirrhosis may be more susceptible to liver damage from Lipitor.
Provided label excerpts specifically list active liver disease (including unexplained persistent transaminase elevations) as contraindication (Sections 4.1 and 5.2). They do not mention hepatitis or cirrhosis susceptibility.
Taking other medications that can damage the liver, such as acetaminophen, may increase the risk of liver damage from Lipitor.
The provided drug interaction excerpts do not mention acetaminophen or liver-damage co-medications.
Some individuals may be more prone to liver damage due to genetic factors.
No genetic susceptibility statement is present in provided excerpts.
Taking the lowest effective dose of Lipitor can help minimize the risk of liver damage.
Label discusses individualized dosing and testing; it does not state lowest effective dose to minimize liver-damage risk.
Avoiding other medications that can damage the liver can minimize the risk of liver damage from Lipitor.
No label statement about avoiding hepatotoxic medications is present in provided excerpts.
Liver function tests (LFTs) can alert a doctor to potential problems while taking Lipitor.
While testing is recommended, the “alert a doctor” phrasing is not directly supported; label states what to test and when (Section 5.2).
Symptoms of liver damage from Lipitor may include fatigue, nausea, abdominal pain, and jaundice.
No symptom list is included in the provided label excerpts.
Contradictions
Low
AI Statement
Liver damage from Lipitor occurs in approximately 0.1% of patients taking the medication.
Label Reference
Persistent elevations (>3x ULN) occurred in 0.7% in clinical trials (Section 5.2).
Important Omissions
Major FDA-listed contraindications include pregnancy (fetal harm; discontinue immediately if pregnancy occurs) and active liver disease/unexplained persistent transaminase elevations, plus hypersensitivity.
Importance:
Moderate
Label-recommended liver-function testing schedule: prior to and at 12 weeks after initiation and after any dose increase, and periodically (e.g., semiannually) thereafter.
Importance:
Moderate
Drug interaction details relevant to safety (e.g., higher risk with cyclosporine and strong CYP3A4 inhibitors; grapefruit juice effects; dose limits such as LIPITOR not exceeding 10 mg with cyclosporine; caution with clarithromycin/itraconazole/protease inhibitors if dose exceeds 20 mg).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes multiple unsupported or imprecise liver-safety claims (quantified incidence, transplant outcome, liver cancer, hepatitis/fatty liver, symptom list, genetic/age susceptibility, hepatotoxic co-medications) and omits pregnancy and active liver disease contraindications and specific interaction/testing recommendations from the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Many liver-related safety statements are not supported by the provided FDA label excerpts (including specific incidence rate, transplant outcome, liver cancer risk, hepatitis/fatty liver associations, and symptom list), and interactions/contraindications are omitted or generalized.
Suggested Improvement
Restrict liver-related claims to what the label excerpts support: transaminase elevations incidence (0.7%), presence of hepatic failure in postmarketing, recommended LFT timing/testing schedule (prior to and at 12 weeks after initiation and dose changes; periodically), and contraindications (active liver disease and pregnancy). For interactions, cite the label-supported CYP3A4 inhibitor/cyclosporine/grapefruit juice guidance and related dose limits/cautions.